1. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр) Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. М., 2008; с. 32.
2. Лапшина Л.А., Шевченко О.С., Бездетко Н.В. Торасемид в кобинированной терапии гипертонической болезни: динамика показателей суточного мониторирования артериального давления и диастолической функции. Материалы V Научно-практической конференции по клинической фармакологии «Достижения и перспективы клинической фармакологии». Киев; с. 230.
3. Подзолков В.И., Можарова Л.Г, Хомицкая Ю.В. Артериальная гипертензия у женщин с климактерическим синдромом. Обзоры клинич. кардиологии. 2005; 1: 35–42.
4. Achhammer J, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
5. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothi-azide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 211–20.
6. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
7. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50–100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Excerpta Medica: Amsterdam 1993; p. 279–82.
8. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of today 1994; 8: 1–28.
9. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5.
10. Cosin J, Diez J and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507–13.
11. DeFronzo RA, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237.
12. Dyckner T, Helmers C, Wester PO. Cardiac dysrhythmias in patients with acute myocardial infarction. Relation to serum potassium level and prior diuretic therapy. Acta Med Scand 1984; 216: 127–32.
13. Dunn CJ, Fitton A, Brogden RN. Torasemide. Review of its pharmacology and therapeutic use. Drugs 1995; 49: 121–42.
14. Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a net work meta-analysis. Lancet 2007; 369: 201–7.
15. Fortuño A, Muñiz P, Ravassa S et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats Hypertension 1999; 34 (1): 138–43.
16. Frishman WH, Goldberger J, Sherman D. Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension. J Clin Hypertens 1987; 3: 520–7.
17. Fu Q, Levine BD. Hypertension and Antihypertensive Therapy in Elderly Women: How Much Do We Really Know? Hypertension 2006; 47 (3): 323–4.
18. Girerd X, Giannattasio C, Moulin C et al. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients. J Am Coll Cardiol 1998; 31 (5): 1064–73.
19. Knauf H, Mutschler E, Velazquez H et al. Torasemide significantly reduces thiazide-induced porassium and magnesium loss despite supraadditive natriuresis. Eur J Clin Pharmacol 2009; 65: 465–72.
20. Lewis CE, Grandits GA, Flack J et al. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Arch Intern Med 1996; 156: 377–85.
21. Perani G, Martignoni A, Muggia C et al. Metabolic effects of the combination of captopril and hydrochlorothiazide in hypertensive subjects. J Clin Pharmacol 1990; 30: 1031–5.
22. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihyper-tensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Gustav-Fischer-Verlag: Stuttgart 1990; 8: 183–209.
23. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gómez C et al. Torasemide-PR in Hypertension Clinical Trial Investigators Group Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther 2008; 26 (2): 91–100.
24. Staessen J, Bulpitt CJ, Fagard R et al. The influence of menopause on blood pressure. J Hum Hypertens 1989; 3: 427–33.
25. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.
26. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patiehts with essential hypertension. Drug Res 1988; 38 (1): 190–3.
27. Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287: 1003–10.
28. Werner U, Werner D, Heinbüchner S et al. Gender is an important determinant of the disposition of the loop diuretic torasemide. J Clin Pharmacol 2010; 50 (2): 160–8.
29. Waddell TK, Dart AM, Gatzka CD et al. Women exhibit a greater age-related increase in proximal aortic stiffness than men. J Hypertens 2001; 19: 2205–12.
30. Zillich AJ, Grag J, Basu S et al. Thiazide diuretics, potassium, and the developnent of diabetes: a quatitative review. Hypertension 2006; 48 (2): 219–24.

О.Н.Ткачева1, Н.В.Шарашкина2, И.М.Новикова2, Н.А.Чухарева2, Н.К.Рунихина2

1 ФГУ ГНИЦ профилактической медицины Минздравсоцразвития РФ;
2 ФГУ НЦ акушерства, гинекологии и перинатологии им. В.И.Кулакова Минздравсоцразвития РФ